AI assistant
Sending…
Lineage Cell Therapeutics Inc. — Major Shareholding Notification 2022
Mar 29, 2022
6895_rns_2022-03-29_d5603ef1-020f-4ba4-8a99-1c8c101e8332.htm
Major Shareholding Notification
Open in viewerOpens in your device viewer
Statement of Changes in Beneficial Ownership - Culley Brian M.����� ������ ���� �����- Culley Brian M. false
| ������' �� ��������� ���� | 2 380 |
| .LINEAGE CELL THERAPEUTICS, INC | |
| Corporation no: 876343 | 10834 |
| - - - | |
| Israel Securities Authority | Tel Aviv Stock Exchange | C002 ( Public ) | Reported via MAGNA: | 29/03/2022 | ||||||
| www.isa.gov.il | www.tase.co.il | Reference: | 2022-02-037012 | Time of broadcast: 09:19 09:19 |
Immediate ReportRegulation 4 of the Securities Regulations, (Periodic and Immediate Reports of Foreign Corporation) 5761-2000
| The corporation is a foreign private issuer as defined by U.S. Securities Laws. |
Attached hereto is a report onStatement of Changes in Beneficial Ownership - Culley Brian M. ����� ������ ���� �����- Culley Brian M.
0001493152-22-007925_isa.pdf
| References of previous documents relating to this matter(the reference does not constitute incorporation by reference): | |
| - - - | |
| Stock Exchange/Market: -1 | Date of revision of form structure: 22/02/2022 |
| Address: HARBOR BAY PARKWAY 1301 , ALAMEDA 94502 CALIFORNIA , U.S.A Tel: 5105213390 , Fax: 5105213389 | |
| E-mail address: [email protected] Company site: biotimeinc.com | |
| Previous names of reporting entity: .BIOTIME, INC | |
| Name of the Signatory: Gerzi Ilan Position of Signatory in the reporting corporation: Attorney/Legal Counsel Name of Employer Company: PEARL COHEN ZEDEK LATZER BARATZ | |
| Address: Derech Menachem Begin 132 , Tel-Aviv 6702101 Telephone: 03-6073777 Facsimile: 03-6073778 E-mail: [email protected] 1 | |
| U.S.A |
More from Lineage Cell Therapeutics Inc.
Report Publication Announcement
2026
May 13
Interim / Quarterly Report
2026
May 13
Earnings Release
2026
May 13
Report Publication Announcement
2026
May 13
Report Publication Announcement
2026
May 13
Interim / Quarterly Report
2026
May 12
Regulatory Filings
2026
May 12
Report Publication Announcement
2026
May 5
Earnings Release
2026
May 5
Investor Presentation
2026
May 4